GLP-1 and Alcohol: What the Labels and Research Say

What the labels say about alcohol

We searched the full prescribing information for Wegovy (semaglutide) and Zepbound (tirzepatide) for guidance on drinking. Neither label contains an instruction about alcohol use. The only mentions are of alcohol swabs for cleaning the skin and the preservative benzyl alcohol in the formulation, which have nothing to do with drinking. MedlinePlus's page on semaglutide injection also does not mention alcohol.

That absence is not a green light. It means the labels leave the question to you and your provider, and the safety topics they do cover are worth thinking about if you drink.

Pancreatitis

Both labels warn that acute pancreatitis (inflammation of the pancreas) has been observed in people taking these medicines. The Zepbound label describes symptoms as persistent or severe abdominal pain, sometimes radiating to the back, which may or may not come with nausea or vomiting, and says to discontinue the medicine if pancreatitis is suspected. The Wegovy Medication Guide says to stop the medicine and call your provider right away.

Separately, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) lists heavy alcohol use among the most common causes of both acute and chronic pancreatitis. It names gallstones as the most common cause of acute pancreatitis. Neither label says that drinking raises pancreatitis risk with these drugs specifically, but because heavy drinking is a known cause on its own, tell your provider about how much you drink, especially if you have had pancreatitis.

Get urgent care for severe or worsening abdominal pain, fever or chills, shortness of breath, or yellowing of the skin or the whites of the eyes. See our GLP-1 side effects guide for the full list of warning signs.

Dehydration, nausea and stomach upset

Nausea, vomiting and diarrhea are the most common side effects of GLP-1 medicines. The Wegovy Medication Guide says these can cause fluid loss that may lead to kidney problems, and that drinking fluids helps reduce the chance of dehydration. The Zepbound label says most reported kidney events occurred in people who had gastrointestinal reactions leading to dehydration.

The labels do not link alcohol to these effects, but the practical overlap is clear. If you already feel nauseated, or are eating very little, a drink may add to an upset stomach. The 2025 nutrition advisory from four U.S. nutrition and obesity societies lists minimal alcohol intake among its eating-habit recommendations for people on GLP-1s. See our guide on what to eat on a GLP-1 for the full picture.

Low blood sugar

The Wegovy and Zepbound labels warn that low blood sugar (hypoglycemia) can occur, mainly when the medicine is combined with insulin or an insulin secretagogue such as a sulfonylurea, which are diabetes drugs. The labels advise lowering the dose of those other medicines and teaching patients the signs of low blood sugar. The labels reviewed do not mention alcohol in this context.

If you take insulin or a sulfonylurea for diabetes, ask your provider specifically how alcohol fits in. Do not assume the absence of a label warning means there is no interaction with your other medicines.

Do GLP-1 medicines reduce drinking? What the research shows

Some people on GLP-1s report wanting less alcohol, and researchers are testing whether the drugs could treat alcohol use disorder (AUD). The strongest controlled evidence we reviewed is one small, early trial, published in JAMA Psychiatry in 2025.

• Design: a phase 2, double-blind, randomized trial of 9 weeks of outpatient treatment in 48 adults with AUD who were not seeking treatment. Participants received once-weekly semaglutide (0.25 mg for 4 weeks, 0.5 mg for 4 weeks, then 1.0 mg for 1 week) or placebo.
• What improved: low-dose semaglutide reduced the amount of alcohol consumed in a laboratory self-administration task, and reduced drinks per drinking day and weekly alcohol craving compared with placebo.
• What did not: semaglutide did not change average drinks per calendar day or the number of drinking days.
• Authors' conclusion: the findings are initial evidence that low-dose semaglutide can reduce craving and some drinking outcomes, and they justify larger clinical trials.

This was not a weight-loss trial, the sample was small, and it lasted 9 weeks. The 2025 joint nutrition advisory describes the same trial as reducing some but not all measures of alcohol use and craving. Neither the Wegovy nor the Zepbound label lists alcohol use disorder as an approved use, and these results do not apply to compounded versions.

If you struggle with alcohol, a GLP-1 is not a substitute for care. Talk to your provider about evidence-based treatment.

Practical guidance

The sources do not set an alcohol limit for people on GLP-1s, so use these steps as questions for your provider rather than rules:

• Tell your provider how much you usually drink, and about any history of pancreatitis, gallstones or liver or kidney problems.
• Notice how you feel. Nausea often peaks when you start or raise a dose, so many people find they tolerate alcohol less well then. If it makes symptoms worse, skip it.
• Do not drink on an empty stomach or when you are vomiting or have diarrhea. Drink water to keep up fluids.
• If you take insulin or a sulfonylurea, ask how to handle alcohol and low blood sugar.
• Know the warning signs of pancreatitis and dehydration, and seek care right away if they appear.
• If your interest in alcohol changes sharply in either direction, mention it to your care team.

You can log doses and symptoms in the Gala GLP-1 app to share patterns with your care team.

How Gala's care team helps

Compounded medications are not FDA-approved. Gala offers compounded semaglutide, compounded tirzepatide and brand-name Ozempic®. A licensed provider reviews your online assessment and prescribes only if it is appropriate for you. If prescribed, your medication ships to your home, you can message your care team with questions about alcohol or side effects, and your provider can adjust your dose.

To see whether a GLP-1 option may be right for you, start your online GLP-1 assessment, or explore the weight loss hub. To learn how compounded products differ from brand-name drugs, read about compounded GLP-1 medications.

This article is for information only and is not medical advice. Talk to your healthcare provider about alcohol and your treatment.

Sources

1. Novo Nordisk. WEGOVY (semaglutide) prescribing information and Medication Guide. FDA-approved label.
2. Eli Lilly. ZEPBOUND (tirzepatide) prescribing information. FDA-approved label.
3. MedlinePlus (NIH). Semaglutide injection.
4. NIDDK (NIH). Symptoms and causes of pancreatitis.
5. Hendershot CS, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025.
6. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory. Obesity Pillars. 2025.

This article is for general information and is not medical advice. Talk to a licensed provider about your own health.